Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | HTR1B | P28222 | 3/20 | 0.43 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4989412 | 0.96 | GPR35 (0.46) | GPR35KDM4EMEN1KMT2AHTR1B | |
| SCHEMBL4248701 | 0.92 | GPR35 (0.48) | GPR35KDM4EMEN1KMT2AAKR1B1 | |
| SCHEMBL4247593 | 0.92 | GPR35 (0.49) | GPR35KDM4EMEN1KMT2AAKR1B1 | |
| SCHEMBL4988821 | 0.92 | MEN1 (0.46) | GPR35KDM4EMEN1KMT2AHTR1B | |
| SCHEMBL4254261 | 0.91 | GPR35 (0.46) | GPR35KDM4EMEN1KMT2AAKR1B1 | |
| SCHEMBL4251118 | 0.90 | GPR35 (0.47) | GPR35KDM4EMEN1KMT2AAKR1B1 | |
| SCHEMBL4250257 | 0.90 | GPR35 (0.49) | GPR35KDM4EMEN1KMT2AHTR1B | |
| SCHEMBL4995314 | 0.88 | ATM (0.52) | GPR35KDM4EMEN1KMT2AHTR1B | |
| SCHEMBL4249890 | 0.87 | GPR35 (0.48) | GPR35KDM4EMEN1KMT2AHTR1B | |
| SCHEMBL4249962 | 0.86 | ACHE (0.55) | GPR35KDM4EMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080076759-A1 | Therapeutic Heterocyclic Compounds 507 | ASTRAZENECA AB (SE) | 2008-03-27 | — | — | US | disclosed |
| US-7285662-B2 | Therapeutic heterocyclic compounds | ASTRAZENECA AB (SE) | 2007-10-23 | — | — | US | disclosed |
| US-20060178372-A1 | Therapeutic quinoline compounds | ASTRAZENECA AB (SE) | 2006-08-10 | — | — | US | disclosed |
| US-7045514-B2 | Therapeutic heterocyclic compounds | ASTRAZENECA AB (SE) | 2006-05-16 | — | — | US | disclosed |
| US-7026314-B2 | Psychological disorders, antidepressants, anxiolytic agents, eating disorders; serotonin receptors antagonist | ASTRAZENECA AB (SE) | 2006-04-11 | — | — | US | disclosed |
| US-20060019947-A1 | Therapeutic chromone compounds | CHAPDELAINE MARC | 2006-01-26 | — | — | US | disclosed |
| US-20050182050-A1 | Therapeutic heterocyclic compounds | ASTRAZENECA AB (SE) | 2005-08-18 | — | — | US | disclosed |
| US-20050096312-A1 | Antiserotonine agents; antidepressants; eating disorders; anxiolytic agents; sleep disorders; gastrointestinal disorders; cardiovascular disorders; muscular disorders; endocrine system diseases; muscular disorders; psychological disorders | ASTRAZENECA AB (SE) | 2005-05-05 | — | — | US | disclosed |
| US-20050085457-A1 | Therapeutic quinolone compounds with 5-ht-antagonistic properties | ASTRAZENECA AB (SE) | 2005-04-21 | — | — | US | disclosed |
| US-20050009818-A1 | Therapeutic heterocyclic compounds | PIERSON EDWARD (US) | 2005-01-13 | — | — | US | disclosed |
| US-20040082591-A1 | Therapeutic heterocyclic compounds | ASTRAZENECA AB (SE) | 2004-04-29 | — | — | US | disclosed |
| EP-1353915-A2 | THERAPEUTIC CHROMAN COMPOUNDS | AstraZeneca AB (SE) | 2003-10-22 | — | — | EP | disclosed |
| EP-1353914-A2 | THERAPEUTIC CHROMONE COMPOUNDS | AstraZeneca AB (SE) | 2003-10-22 | — | — | EP | disclosed |
| EP-1353913-A2 | THERAPEUTIC HETEROCYCLIC COMPOUNDS | AstraZeneca AB (SE) | 2003-10-22 | — | — | EP | disclosed |
| WO-2003037872-A1 | THERAPEUTIC QUINOLINE COMPOUNDS WITH 5-HT-ANTAGONISTIC PROPERTIES | ASTRAZENECA AB (SE) | 2003-05-08 | — | — | WO | disclosed |
| WO-2003037871-A1 | THERAPEUTIC QUINOLONE COMPOUNDS WITH 5-HT-ANTAGONISTIC PROPERTIES | ASTRAZENECA AB (SE) | 2003-05-08 | — | — | WO | disclosed |
| US-20030013708-A1 | Therapeutic heterocyclic compounds | ASTRAZENECA AB (SE) | 2003-01-16 | — | — | US | disclosed |
| WO-2002055013-A2 | THERAPEUTIC CHROMONE COMPOUNDS | ASTRAZENECA AB (SE) | 2002-07-18 | — | — | WO | disclosed |
| WO-2002055012-A2 | THERAPEUTIC HETEROCYCLIC COMPOUNDS | ASTRAZENECA AB (SE) | 2002-07-18 | — | — | WO | disclosed |
| WO-2002055014-A2 | THERAPEUTIC CHROMAN COMPOUNDS | ASTRAZENECA AB (SE) | 2002-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076759-A1 | Therapeutic Heterocyclic Compounds 507 | HTR1A, HTR1B, HTR1D | GPR35 113/4885KDM4E 1536/4885MEN1 382/4885 |
| US-20060178372-A1 | Therapeutic quinoline compounds | HTR1B, HTR3B, HTR1A | GPR35 326/4885KDM4E 1274/4885MEN1 192/4885 |
| US-20050085457-A1 | Therapeutic quinolone compounds with 5-ht-antagonistic properties | HTR1B, HTR1A, HTR1D | GPR35 298/4885KDM4E 674/4885MEN1 236/4885 |
| US-20050009818-A1 | Therapeutic heterocyclic compounds | HTR1B, HTR1D, HTR1A | GPR35 214/4885KDM4E 1622/4885MEN1 285/4885 |
| US-20050182050-A1 | Therapeutic heterocyclic compounds | HTR1B, HTR1D, HTR1A | GPR35 214/4885KDM4E 1622/4885MEN1 285/4885 |
| US-20030013708-A1 | Therapeutic heterocyclic compounds | HTR1A, HTR1D, HTR1B | GPR35 251/4885KDM4E 1450/4885MEN1 215/4885 |
| US-20040082591-A1 | Therapeutic heterocyclic compounds | HTR1A, HTR1D, HTR1B | GPR35 204/4885KDM4E 1583/4885MEN1 242/4885 |
| US-20060019947-A1 | Therapeutic chromone compounds | HTR1B, HTR3B, HTR1A | GPR35 696/4885KDM4E 1678/4885MEN1 419/4885 |
| US-20050096312-A1 | Antiserotonine agents; antidepressants; eating disorders; anxiolytic agents; sleep disorders; gastrointestinal disorders; cardiovascular disorders; muscular disorders; endocrine system diseases; muscular disorders; psychological disorders | HTR1D, HTR1B, HTR1A | GPR35 160/4885KDM4E 942/4885MEN1 260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.